

The Braingrade Memory Implant System will create a brighter future for patients with Alzheimer's Disease.

**Problem:** Alzheimer's Disease (AD) is the most expensive disease in the US, has no cure, and 1 in 4 people die with it. Current treatments are so bad that >50% of patients discontinue use within one year, and the clinical guidelines suggested they not be reimbursed.

**Solution:** In AD, the electrophysiology of the memory circuit is disrupted, leading to desynchronized activity and cognitive deficits. The system measures network activity of the memory circuit and stimulates with precise stimulation to restore synchrony and proper memory function while providing neuroregenerative and neuroprotective effects.

**Economic Value:** Institutionalized care for AD patients is \$68,000 per year on average and current treatments cost \$56,000 per year. The BMI will extend patient independence and keep them out of institutional care.

**Market:** 55 M people with AD today growing to 130 M in 2050. Over \$277 Billion spent on care for AD patients per year with 1 in 5 of all medicare dollars going to AD patients. TAM estimated at \$1.6 Trillion.

Platform for network interaction allows future indications such as depression, OCD, tourette's, and more.

**Competition:** Only approved treatments are pharmaceuticals (status quo), but they are labeled insufficient by patients and physicians. Direct competitors are relying on 20 year old technology.

We are the only company addressing the challenge of getting information into the brain through networked deep structure access, setting us apart from BCI tech such as Neuralink and Paradromics.

**Business Model:** Direct sales to service providers (hospitals) near average reimbursement payment for deep brain stimulators (\$23,500) at 80% margin. Obtainable market supports >40,000 implants per year.

**Go-to-Market:** Market adoption is accelerated through careful selection of clinical trial sites as business partners in penetrating select integrated delivery networks. Use of Key Opinion Leaders in Alzheimer's Disease pharmacology as partners in publications to gain additional providers.

**IP:** Patent portfolio consists of 4 US/EU issued patents and 1 pending patent application, along with trade secret development surrounding electrode manufacturing, owned by the company.

**Timeline:** Two years to clinical trial, five years to market (CE). Clinical trial time expedited due to faster effects than pharmaceuticals.

**Timing:** Multiple studies with over 300 implanted patients demonstrate positive effect in memory and cognition through implantable neurostimulation, and physicians and scientists have identified key features for effective commercial device.

**\$11M min Raise - Milestones:** Completion of human study, non-human primate chronic implantation study, and development and preclinical testing of hardware and software.



## Braingrade

Website: [www.braingrade.io](http://www.braingrade.io)  
Industry: Medical Devices, Consumer Health, Neuromodulation  
Stage: Pre-product  
FDA Contact  
Devices in hand for test  
Entity: German GmbH -> Delaware C-Corp  
Founded: February 2020  
Location: Austin, Texas

### Mission

Enhance the human brain

### Funding History

\$650,000 raised through angel and founder investments

### Team

Peter Schlecht, MS, CEO  
Successful Serial Entrepreneur

Nick Halper, COO and Regulatory  
Former Executive at Blackrock  
Neurotech

Felix Deku, PhD, Head of Electrode  
Development  
Former Director of Microfabrication at  
Neuralink

Prof. Harbi Sohal, PhD, Head of Systems  
Engineering  
MedTech Rising Star and Forbes 30  
under 30 on Science List

Rob Edgington, PhD, Head of Data  
Science and AI  
Founder of Paradromics and former  
Head of AI

Prof. Christian Hauptmann, PhD, Head of  
Neural Engineering  
Nearly neuromodulation 50 patents

Total Team: 8 FTE, 6 PTE